BrainsWay (BrainsWay) Change In Receivables : $1.23 Mil (TTM As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is BrainsWay Change In Receivables?

BrainsWay's change in receivables for the quarter that ended in Mar. 2024 was $-0.57 Mil. It means BrainsWay's Accounts Receivable increased by $0.57 Mil from Dec. 2023 to Mar. 2024 .

BrainsWay's change in receivables for the fiscal year that ended in Dec. 2023 was $1.09 Mil. It means BrainsWay's Accounts Receivable declined by $1.09 Mil from Dec. 2022 to Dec. 2023 .

BrainsWay's Accounts Receivable for the quarter that ended in Mar. 2024 was $4.34 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. BrainsWay's Days Sales Outstanding for the three months ended in Mar. 2024 was 43.53.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. BrainsWay's liquidation value for the three months ended in Mar. 2024 was $29.60 Mil.

BrainsWay Change In Receivables Historical Data

The historical data trend for BrainsWay's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrainsWay Change In Receivables Chart

BrainsWay Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-2.50

-0.10

-0.85

1.46

1.09

BrainsWay Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-0.49	1.54	0.34	-0.07	-0.57

BrainsWay Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.23 Mil.

BrainsWay (OTCPK:BRSYF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

BrainsWay's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	4.339	/	9.095	*	91
=	43.53

2. In Ben Graham's calculation of liquidation value, BrainsWay's accounts receivable are only considered to be worth 75% of book value:

BrainsWay's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	47.578	-	23.146	+	0.75 * 4.339	+	0.5 * 3.832
=	29.60

BrainsWay Change In Receivables Related Terms

Thank you for viewing the detailed overview of BrainsWay's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

BrainsWay (BrainsWay) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BrainsWay Ltd (OTCPK:BRSYF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

BWAY:USA BWAY:Israel

Address

19 Hartum Street, 3rd Floor, Bynet Building, Har Hotzvim, Jerusalem, ISR, 9777518

Website

https://www.brainsway.com

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.